Ciravolo et al. have already suggested a mechanism of anti-HER2 resistance by the increased binding efficiency of HER2+ exosomes to trastuzumab in progressive HER2+ breast cancers as compared to earlier stages of breast cancer [40]. The gene discussed is ERBB2; the disease is breast cancer.